Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-25-Q-9202
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) Defense Health Agency is seeking pharmaceutical manufacturers to submit quotes for the Military Health System's Pharmacy Uniform Formulary program. The solicitation covers newly approved drugs across several therapeutic classes, including Pain Agents, Antivirals, and Targeted Immunomodulatory Biologics, to be reviewed at the May 2025 Pharmacy and Therapeutics (P&T) Committee meeting. Specifically, manufacturers must provide pricing and clinical information for drugs like Journavx, Prevymis, Selarsdi, Steqeyma, and Yesintek. The evaluation will consider relative clinical and cost effectiveness in recommending formulary placement and cost-sharing classifications. Key dates include a pre-quotation teleconference on March 5, 2025, and quote submissions due by March 20, 2025, with manufacturers required to submit pricing for all NDC package sizes and respond to specific clinical questions about their drugs.
The solicitation does not have a specific set-aside designation and will be open to all qualified pharmaceutical manufacturers. The place of performance is located in San Antonio, TX 78230. Manufacturers must provide pricing for two primary agreement types: Uniform Formulary Blanket Purchase Agreements (UF BPA) for Military Treatment Facilities and TRICARE Mail Order Pharmacy, and Uniform Formulary Additional Discount Program (UF ADP) agreements for TRICARE retail network pharmacies. The agreements will be effective upon signature by the Contracting Officer and continue until the drug class is reevaluated or terminated. Pricing quotes must remain valid for 180 days, and manufacturers must address potential prior authorization requirements and step therapy considerations for different drug indications. The solicitation allows for up to 10 NDCs per submission, with potential for additional NDC tables to be requested through the RFQ points of contact.
Notice text
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following May 2025 newly approved drugs will be reviewed:
a. Journavx - Pain Agents - Pain Miscellaneous
b. Prevymis -Antivirals - NA
c. Selarsdi - Targeted Immunomodulatory Biologics - Interleukin 23
d. Steqeyma - Targeted Immunomodulatory Biologics - Interleukin 23
e. Yesintek - Targeted Immunomodulatory Biologics - Interleukin 23
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9202.
Pre-quotation teleconference is on March 5, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Files
| File | Type | Posted |
|---|---|---|
| Price List - Prevymis - Antivirals - NA.xlsx | XLSX spreadsheet | |
| Price List - Yesintek - TIB - IL23.xlsx | XLSX spreadsheet | |
| RFQ HT9402-25-Q-9202 NAD.pdf | ||
| Price Appendix FAQ NAD.pdf | ||
| Price List - Selarsdi - TIB - IL23.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Journavx - Pain Agents - Pain Misc..xlsx | XLSX spreadsheet | |
| Price List - Steqeyma - TIB - IL23.xlsx | XLSX spreadsheet |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity